News

Sema4 Launches High-Capacity COVID-19 Testing to Address Critical Need Across Connecticut and New York

Sema4 announced that it is now performing rapid molecular testing for the detection of SARS-CoV-2, the coronavirus responsible for COVID-19.

SEMA4 PRESS RELEASE | 03.12.20

Former Senior FDA Official Dr. Rachel Sherman Joins Sema4 Board of Directors

Sema4 announced the appointment of Rachel Sherman, MD, MPH, to its Board of Directors. Dr. Sherman is the former Principal Deputy Commissioner of Food and Drugs at the U.S. Food and Drug Administration (FDA).

CLINICAL OMICS | 03.03.20

Sema4, VieCure Launch Precision Oncology Collaboration

Clinical OMICs published an article covering Sema4’s strategic alliance with VieCure. The piece covers how the collaboration between the two companies is accelerating precision oncology care.

SEMA4 PRESS RELEASE | 03.02.20

Sema4 and VieCure Announce Strategic Collaboration to Accelerate Precision Oncology Care

Sema4, a patient-centered health intelligence company, and VieCure, an artificial intelligence (AI) informatics company with a leading point-of-care clinical decision support platform and a comprehensive electronic medical record (EMR) in oncology, today announced a strategic collaboration designed to help oncologists deliver personalized care and treatment to their patients.
READ MORE

Governor’s Innovation Fellowship in Connecticut | 02.24.20

Sema4 Participates in Governor’s Innovation Fellowship

Sema4 is one of nine companies participating in the Governor’s Innovation Fellowship in Connecticut. The office of Connecticut Governor Ned Lamont issued a press release on the Fellowship, a pilot program enabling college graduates to start their careers with a job at select growing companies, including Sema4. The announcement referenced Sema4 as “the fastest-growing health intelligence company in the country.”
READ MORE

CLINICAL OMICS | 02.11.20

Moving the Diagnostics Needle for Personalized Care

Clinical OMICs featured comments that Eric Schadt, Ph.D., Founder and CEO of Sema4, made in a recent panel discussion titled “Transformative Technologies: Previewing the Value Proposition and Outlook for Disruptive Tools Designed to Enable Personalized Medicine.” The panel was chaired and moderated by Michael Pellini, M.D., a member of Sema4’s Board of Directors. At Sema4, “the focus is on developing actionable data from patients, while also keeping the patient in control of their own health data,” shared Eric. Read the full article below by Chris Anderson, Editor-in-Chief at Clinical Omics.
READ MORE

SEMA4 PRESS RELEASE | 11.14.19

Sema4 Appoints Biotech Leader Joel Sendek as Chief Financial Officer

Sema4 announces the appointment of Joel Sendek as Chief Financial Officer. Mr. Sendek has more than 25 years of financial leadership experience in the pharmaceutical and biotechnology sector, including overseeing the successful initial public offerings at his last two companies.
READ MORE

SEMA4 PRESS RELEASE | 10.11.19

Sema4 Applies Data-Driven Approach to Expanded Carrier Screening

Sema4 Applies Data-Driven Approach to Expanded Carrier Screening, and Will Soon Utilize Exome Sequencing for Genetic Testing Powered by the Centrellis™ Health Intelligence Platform, Sema4’s Expanded Carrier Screen with Personalized Residual Risk Will Help Inform Pregnancy Planning Decisions.
READ MORE

GENOMEWEB | 08.29.19

Sema4 Lands New Investors, Continues to Expand

Sema4 has landed its first outside investment, allowing it to continue its rapid growth. Sema4 updated its investors webpage to include five new entities: private equity behemoth Blackstone; venture capital funds Section 32, OakHC/FT, and Decheng Capital; and Connecticut Innovations, the state’s quasi-public investment agency.
READ MORE

SEMA4 PRESS RELEASE | 08.01.19

Sema4 Announces Location of its Second Connecticut Lab

Sema4 announces location of its second Connecticut Lab as part of the company’s commitment to the state’s biotech industry. The new 70,000 square foot facility in Stamford will soon be home to 300+ employees. Governor Ned Lamont and U.S. Representative Jim Himes joined a ceremony on August 1st to commence construction.
READ MORE